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| INTRODUC TI ON
Gastric cancer is one of the most common cancers, with very specific geographical, ethnic and socioeconomic differences in incidence. Typically gastric cancer has a male predominance and is diagnosed at a median age of 70 years, whereas only 1% of patients are <34 years at diagnosis. 2 Pregnancy-associated gastric cancer, defined as a diagnosis of gastric cancer during pregnancy or up to 1 year after delivery, is estimated to complicate 0.026%-0.1% of all pregnancies. 3 Gastric cancer is staged according to the American Joint Committee on Cancer/Union for International Cancer Control TNM staging system, based upon tumor size (T), lymph node invasion (N), and metastatic disease (M). Early gastric cancer is limited to the mucosa or submucosa (T1), whereas the tumor is assumed to be clinically localized once the muscular layer (T2) is invaded. Stage I gastric cancer is limited to the stomach, whereas in stage II lymph nodes are affected or the tumor spreads to the subserosa or serosa (T3-4aN0). In stage III the tumor invades both (sub)serosa and lymph nodes, in stage IV the tumor has spread to the adjacent organs with lymph nodes affected or distant organs. The stage distribution in the general population is 21.6% for stage I, 22 .3% for stage II, 44.0% for stage III, and 12.1% for stage IV. 4 Pregnant women are at risk for delayed diagnosis of gastric cancer because symptoms may be regarded as gestational features and because of the reluctance to perform invasive diagnostic procedures such as gastroscopy. 5 As a result, gastric cancer is often diagnosed in more advanced cancer stages. Gastric cancer that invades through the submucosa stage II or higher with no evidence of distant metastases, or locally advanced inoperable disease can be treated with curative intent by surgical resection and perioperative chemotherapy. 6 In locally advanced unresectable or metastatic gastric cancer, surgery is not a feasible option and palliative chemotherapy can be considered. Standard cytotoxic treatment for primary gastric cancer consists of a platinum-fluoropyrimidine-based regimen, such as FOLFOX (5- 
Results:
In total, 13 women with gastric cancer during pregnancy were registered between 2002 and 2018. Median gestational age at diagnosis was 22 weeks (range 6-30 weeks). Twelve women were diagnosed with advanced disease and died within 2 years after pregnancy, most within 6 months. In total, eight out of 10 live births ended in a preterm delivery because of preeclampsia, maternal deterioration, or therapy planning. Two out of six women who initiated chemotherapy during pregnancy delivered at term. Two neonates prenatally exposed to chemotherapy were growth restricted and one of them developed a systemic infection with brain abscess after preterm delivery for preeclampsia 2 weeks after chemotherapy. No malformations were reported.
Conclusions:
The prognosis of gastric cancer during pregnancy is poor, mainly due to advanced disease at diagnosis, emphasizing the need for early diagnosis. Antenatal chemotherapy can be considered to reach fetal maturity, taking possible complications such as growth restriction, preterm delivery, and hematopoietic suppression at birth into account. KEYWORDS chemotherapy, gastric cancer, maternal outcome, obstetric outcome, pregnancy
Key message
Early recognition of symptoms of gastric cancer in pregnant women allows curative treatment but is hampered by low incidence of complaints in early cancer and the overlapping symptoms with pregnancy. Chemotherapy during pregnancy might be considered if parents are counseled for neonatal risks. while avoiding preterm birth or pregnancy termination as much as possible. 7 To date, the relative safety of antenatal chemotherapy is mainly demonstrated for treatments used in breast and cervical cancer, and lymphomas, but experience with gastric cancer is limited. 7 Most large case series on gastric cancer during pregnancy do not report on the use and consequences of cytotoxic treatment and include only Asian patients. 3, 8, 9 However, biological behavior and response to treatment may show geographic differences. 10 Therefore, we selected all women with a diagnosis and/or treatment of gastric cancer during pregnancy from the international "cancer in pregnancy" International Network on Cancer, Infertility and Pregnancy (INCIP) registry (www.cance rinpr egnan cy.org). We conducted a review of cases where chemotherapy was initiated during pregnancy and assessed neonatal outcome in this population. Referring physicians were contacted to complete missing data.
| MATERIAL AND ME THODS
Small-for-gestational-age (SGA) was defined as a birthweight below the 10th centile, and centiles were corrected for gestational age, sex, maternal height, maternal weight, ethnicity, and parity according to the calculator from the Gestation Network (www.gesta tion. net; v8.0.2, 2018) Preterm delivery was defined as birth before 37 weeks of gestation.
In addition, we performed a narrative review and searched for case reports and case series, as well as articles on treatment options for gastric cancer during pregnancy, published in the English literature. Articles were identified by a PUBMED search with the following MESH terms: "pregnancy", "gastric cancer", and "chemotherapy" and variations thereof. For statistics, we used descriptive analysis.
Comparative analysis was not performed because of the small number of patients.
| Ethics approval
The international registration study "Cancer in Pregnancy" was approved by the Ethics Committee of University Hospitals of Leuven (B322201421061) 23 May 2014 and participating centers according to local policies.
| RE SULTS

| Patient and tumor characteristics
In total, 13 women diagnosed with primary or recurrent gastric cancer during pregnancy were retrieved from the registry (see Supplementary material, Table S1 ). They were diagnosed between March 2002 and November 2017 in 6 countries (The Netherlands, n = 5; USA, n = 3; Belgium, n = 2; Czech Republic, n = 1; Italy, n = 1;
and France, n = 1). One woman with a diagnosis of gastric carcinoma in situ treated with surgery and in remission for 1 year before pregnancy was excluded.
All women, except one, were diagnosed with advanced or metastatic disease (12/13, 92.3%). Patient demographics are described in 
| Surgical and chemotherapeutic management during pregnancy
One woman with stage II cancer started with chemotherapy at 23 weeks of gestation followed by curative gastrectomy after delivery. In total, 10 women had ongoing pregnancies with inoperable gastric cancer and in 5 women chemotherapy was initiated in the second trimester of pregnancy. The chemotherapeutic regimens used during pregnancy were: 5-FU, FOLFOX and carboplatin/paclitaxel. One woman underwent surgery with a curative intent but was diagnosed with intestinal metastasis perioperatively and initiated palliative chemotherapy after elective cesarean section at 32 weeks.
Four patients received no definitive surgical or cytotoxic treatment during pregnancy aside from adnexectomies.
| Obstetrical outcome
As described in Table 1 , there was 1 termination of pregnancy, 2 pregnancy losses and 10 live births. One woman pregnant with twins opted for a termination of pregnancy at 23 weeks of gestation because of metastatic disease. One woman died from the disease 2 weeks after diagnosis at 22 weeks of gestation. One woman miscarried at 19 weeks of gestation following an exploratory laparotomy and adnexectomy. Three women underwent an emergency cesarean section for preeclampsia between 27 and 33 weeks of gestation, and another was delivered at 29 weeks of gestation by cesarean section because of clinical maternal deterioration. Four women had an iatrogenic preterm delivery for therapy planning. Only 2 women delivered at term, both received chemotherapy during pregnancy and had an elective cesarean section for maternal reasons.
| Maternal outcome
All mothers with stage IV gastric cancer were deceased within 24 months after pregnancy, the majority within 6 months. Overall 1-year survival was 31%. The only woman in remission 12 months after diagnosis had stage II gastric cancer and was treated with chemotherapy during pregnancy followed by gastrectomy.
| Outcome of the children
In total 10 pregnancies ended in a live birth. All six neonates prenatally exposed to chemotherapy were born without congenital malformations and all, except one with a birthweight of 2950 g and term delivery, were admitted to the neonatal intensive care unit, mostly for prematurity (4/5 or 80%). One infant born at term was admitted for neonatal abstinence syndrome due to maternal use of methadone. Two neonates prenatally exposed to chemotherapy, to 6 cycles FOLFOX and 3 cycles carboplatin/paclitaxel, respectively, (2/6 or 33%) were SGA at birth. The four non-exposed neonates were admitted to the neonatal intensive care unit for prematurity and two of them where SGA (2/4 or 50%).
The neonatal period of one child born at 32 weeks of gestation, 
| Results of narrative literature review
The largest review to date of 137 Japanese women with pregnancyassociated gastric cancer was published in 2009; one-third of the women with reported timing of delivery were diagnosed with gastric cancer postnatally. 3 In the literature we identified five women receiving a 5-FUbased regimen for advanced gastric cancer during pregnancy, with re-assuring fetal outcomes. [11] [12] [13] Details are summarized in Table 3 .
One woman received paclitaxel and S1 (tegafur [=prodrug of active substance 5-FU], gimeracil, oteracil) and delivered a growth restricted baby at 34 weeks of gestation. 14 after prenatal exposure to S1 and taxanes (cases not included as reported in Japanese language). 14 Five-year survival in young (≤40 years) patients is 47.6% in general, but is highly dependent on tumor stage (range 83.3% for stage I and 0% for stages III and IV). 15 Table 4 . [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Albeit, in clinical practice, most chemotherapeutic agents are given in combination regimens with co-medication, which might also influence the placental transfer through drug interactions.
| D ISCUSS I ON
Most pregnant patients presented with extensive intra-abdominal disease that theoretically might provoke spontaneous preterm contractions. Interestingly all preterm deliveries, except 1, were iatrogenic for oncological or obstetrical reasons. Four out of 10 infants were SGA and this is of special interest because perinatal morbidity and mortality, and cardiovascular and metabolic diseases, are more frequently seen in SGA children than in children of average weight (according to gestational age) at birth. 30 SGA in this population might be explained by the poor maternal general and nutritional status inherent to gastric cancer. In addition, 2 of these children were prenatally exposed to chemotherapy, which is also reported to be associated with SGA. 7 In this series 3 women developed preeclampsia, possibly explained by the relatively high maternal age (diagnoses at the age of 27, 37 and 39 for the 3 cases, respectively Agents with low molecular weight (<500 g/mol) and low protein binding will easily cross the placenta. may be administered during pregnancy (from the second trimester onwards) so as to not delay treatment and to enhance fetal maturity. In patients diagnosed with advanced stages of disease, where no cure is possible, immediate onset of systemic (palliative) treatment might be indicated to treat symptoms and to enhance fetal maturity if there is a wish to continue pregnancy. In early pregnancy, and especially in advanced cases, termination of pregnancy can also be considered. Available case reports on chemotherapy during pregnancy for gastric and colorectal cancer suggest that 5-FU-based regimens (i.e. FOLFOX) are feasible. [11] [12] [13] [14] 26 In general, the use of cytotoxic drugs can only be justified if the risks of both mother and child are balanced and the benefits for maternal outcome outweigh the possible adverse effects on the child.
Studies on the short-term neurocognitive development of children reveal that preterm delivery rather than prenatal exposure to cancer treatment is responsible for impaired cognitive outcome. 19 However, long-term outcome of children prenatally exposed to chemotherapy remains under investigation and further follow up of these children is indispensable.
Although this series on western patients is small, we report on the use of chemotherapy for gastric cancer during pregnancy and the neonatal outcome in detail including follow up. Continuous prospective registration of cases will facilitate future patient counseling. International collaboration is welcomed in order to collect data in larger numbers to improve treatment approach during pregnancy.
| CON CLUS ION
In summary, gastric cancer during pregnancy is a rare diagnosis.
Women present usually in advanced stage and have a poor prognosis. Early recognition of symptoms is indispensable for diagnosis at a curative stage. In pregnant women with persistent gastrointestinal symptoms that cannot be explained by pregnancy alone there should be a low threshold for further diagnostic procedures. While balancing maternal and fetal risks, the initiation of chemotherapy during pregnancy may be considered in order to reach fetal maturity.
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